Biologics and Biosimilars Market Analysis 2026

Global Biologics and Biosimilars Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Biologics and Biosimilars Market Report Description

We have various report editions of Biologics and Biosimilars Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The April 2025 “Liberation Day Tariffs” (10–46%) have disrupted global pharmaceutical trade, raising costs for APIs, packaging, and machinery from China and India. Generic drug makers, biopharma, vaccines, and CMOs face higher expenses, supply chain delays, and regulatory hurdles, while EU retaliation has further strained U.S. exports. Clinical trials are also delayed due to tariffs on drugs and kits. In this landscape, market research is vital, providing real-time data on pricing, suppliers, and tariff impacts to help companies optimize supply chains, find alternative hubs, and maintain competitiveness.

Biologics and Biosimilars Market Insights Video

Competitive Landscape of the Biologics and Biosimilars Market

The competitive landscape of the Biologics and Biosimilars Market is characterized by intense competition among key players such as Amgen Inc., Pfizer Inc., and Novartis AG, among others. These companies dominate the market with their extensive portfolios of biologic drugs and biosimilar products. Strategic collaborations, mergers and acquisitions, and investments in research and development are common strategies employed to maintain market dominance and drive innovation. Regulatory approvals, product quality, and pricing strategies also play significant roles in shaping the competitive dynamics of the market.

June 2022: Aeglea BioTherapeutics reported that it was unsuccessful in obtaining a biologics license application (BLA) from the FDA. The FDA declined to file the company's biologic pegzilarginase.

(Source: https://ir.aeglea.com/press-releases/news-details/2022/Aeglea-BioTherapeutics-Receives-Refusal-to-File-Letter-from-FDA-for-Pegzilarginase-for-the-Treatment-of-Arginase-1-Deficiency/default.aspx#:~:text=(NASDAQ%3A%20AGLE)%2C%20a,regarding%20the%20company's%20Biologics%20License )

Top Companies Market Share in Biologics and Biosimilars Industry: (In no particular order of Rank)

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive)

Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Biologics and Biosimilars Market

Which Region Dominates the Biologics and Biosimilars Market in 2024?

According to Cognitive Market Research, North America dominates the Biologics and Biosimilars market due to several factors. It boasts a robust regulatory framework, advanced healthcare infrastructure, and high healthcare expenditure, facilitating the development and adoption of biologic drugs and biosimilars. Additionally, favorable reimbursement policies and strong intellectual property protection encourage investment and innovation in the region. Moreover, the presence of key market players and extensive research and development activities contribute to North America's largest market share in the Biologics and Biosimilars market.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific region is experiencing the fastest Compound Annual Growth Rate (CAGR) in the Biologics and Biosimilars market due to several factors. These include increasing healthcare expenditure, rising prevalence of chronic diseases, and expanding access to healthcare across the region. Additionally, supportive regulatory frameworks, growing investments in research and development, and strategic partnerships contribute to the rapid growth of the Biologics and Biosimilars market in the Asia Pacific region, fostering innovation and market expansion.

 

The current report Scope analyzes Biologics and Biosimilars Market on 6 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (East Africa, West Africa, North Africa, South Africa)

The above graph is for illustrative purposes only.

North America Biologics and Biosimilars Market Analysis

According to Cognitive Market Research, the global Biologics and Biosimilars market size was estimated at USD 521584.20 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 208633.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Biologics and Biosimilars market with a market size of USD 164611.97 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. The demand is amplified by the nation's advanced healthcare infrastructure.
• The Canada Biologics and Biosimilars market had a market share of USD 25036.04 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. This is due to high healthcare expenditure.
• The Mexico Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 18985.66 million in 2024.

Europe Biologics and Biosimilars Market Analysis

According to Cognitive Market Research, the global Biologics and Biosimilars market size was estimated at USD 521584.20 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 156475.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.

• The United Kingdom Biologics and Biosimilars market had a market share of USD 26287.84 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. In the UK, Biologics and Biosimilars sales witness an upswing due to Growing demand for affordable healthcare solutions.
• The France Biologics and Biosimilars market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 14395.72 million in 2024.
• According to Cognitive Market Research, the Germany Biologics and Biosimilars market size was valued at USD 30982.10 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period. In Germany, Biologics and Biosimilars sales surged due to established healthcare systems that promote biosimilar adoption.
• The Italy Biologics and Biosimilars market is projected to witness growth at a CAGR of 5.9% during the forecast period, with a market size of USD 13456.87 million in 2024.
• The Russia Biologics and Biosimilars market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 24253.67 million in 2024.
• The Spain Biologics and Biosimilars market is projected to witness growth at a CAGR of 5.6% during the forecast period with a market size of USD 12830.97 million in 2024
• The Luxembourg Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.6% during the forecast period, with a market size of USD 4850.73 million in 2024.
• The Portugal Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.3% during the forecast period, with a market size of USD 3285.98 million in 2024.
• The Greece Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 1877.70 million in 2024.
• Rest of Europe's Biologics and Biosimilars market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 24253.67 million in 2024.

Asia Pacific Biologics and Biosimilars Market Analysis

According to Cognitive Market Research, the global Biologics and Biosimilars market size was estimated at USD 521584.20 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 119964.37 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Biologics and Biosimilars market size was valued at USD 53983.96 million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. Biologics and Biosimilars sales surge in China due to increasing healthcare expenditure.
• The Japan Biologics and Biosimilars market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 16555.08 million in 2024.
• The India Biologics and Biosimilars market had a market share of USD 14395.72 million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period. This is due to ing prevalence of chronic diseases.
• The South Korea Biologics and Biosimilars market is projected to witness growth at a CAGR of 9.1% during the forecast period, with a market size of USD 11996.44 million in 2024.
• The Australia Biologics and Biosimilars market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD 6238.15 million in 2024.
• The South East Asia Biologics and Biosimilars market is projected to witness growth at a CAGR of 11.0% during the forecast period, with a market size of USD 8277.54 million in 2024.
• The Rest of Asia Pacific Biologics and Biosimilars market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 8517.47 million in 2024.

South America Biologics and Biosimilars Market Analysis

According to Cognitive Market Research, the global Biologics and Biosimilars market size was estimated at USD 521584.20 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 26079.21 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Biologics and Biosimilars market size was valued at USD 11161.90 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. Biologics and Biosimilars sales flourish in Brazil due to increasing healthcare investments.
• Argentina Biologics and Biosimilars market had a market share of USD 4381.31 million in 2024 and is projected to grow at a CAGR of 8.3% during the forecast period. This is due to rising demand for affordable treatment options.
• Colombia Biologics and Biosimilars market is projected to witness growth at a CAGR of 7.2% during the forecast period with a market size of USD 2321.05 million in 2024.
• Peru Biologics and Biosimilars market is projected to witness growth at a CAGR of 7.6% during the forecast period with a market size of USD 2138.50 million in 2024.
• Chile Biologics and Biosimilars market is projected to witness growth at a CAGR of 7.7% during the forecast period with a market size of USD 1877.70 million in 2024.
• The Rest of Latin America Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 4198.75 million in 2024.

Middle East Biologics and Biosimilars Market Analysis

According to Cognitive Market Research, the global Biologics and Biosimilars market size was estimated at USD 521584.20 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 10431.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031.

• The GCC Countries Biologics and Biosimilars market is projected to witness growth at a CAGR of 8.5% during the forecast period with a market size of USD 4464.76 million in 2024. Biologics and Biosimilars sales flourish due to increasing healthcare investments.
• The Egypt Biologics and Biosimilars market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 1095.33 million in 2024.
• The South Africa Biologics and Biosimilars market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 1648.21 million in 2024. Biologics and Biosimilars sales flourish in South Africa due to rising demand for affordable treatment options.
• The Turkey Biologics and Biosimilars market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 897.12 million in 2024.
• The Nigeria Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 1095.33 million in 2024.
• The Rest of MEA Biologics and Biosimilars market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 1230.94 million in 2024.

Author's Conclusion

Author's Detail

Supriya Yadav

Research Analyst

LinkedIn | Profile | Book Appointment

Supriya Yadav is a dedicated market research professional with expertise in the aerospace and defence industry. At Cognitive Market Research, she focuses on delivering strategic insights into aviation advancements, defence technologies, and global security trends shaping the future of the sector.

Her research covers areas such as military modernization, commercial aviation growth, space exploration, and defence procurement strategies. With a strong analytical mindset and attention to technological evolution, Supriya provides data-driven intelligence that supports innovation, strategic planning, and informed decision-making within the aerospace and defence domain.